Abstract

Objective: To study the significance of Cripto-1,which plays an important role in EpitheliaI-Mesenchymal Transition (EMT),and its prognosis in breast cancer.Methods: Immunohistochemistry for Cripto-1 was performed on 205 cases of breast cancer using LSAB method.The relationship between Cripto-1,E-cadherin (E-CD),β-catenin and various pathologic factors in breast cancer was analyzed.Additionally,the relationship between the Cripto-1 protein and reoccurrence, metastasis,and survival time in patients was analyzed.Results: (1) Cripto-1 was mainly expressed in the plasma of tumor cells and the positive rate was 82.9% (170/205).The expression of Cripto-1 was positively correlated with pathologic stage (r=0.418,P=0.000),Her2/neu (r=0.223,P=0.001),lymph node metastasis (r=0.293,P=0.000),extranodal extension (r=0.206,P=0.003),and distant metastasis (r=0.174,P=0.012).There was no correlation between Cripto-1 and ER,PR,or age.There was a positive correlation between the expression of Cripto-1 and histological grade (r=0.141,P=0.044)in 179 invasive ductal carcinomas.(2) E-CD was mainly expressed in the membrane of tumor cells.And β-catenin was expressed in both the membrane and the plasma of tumor cells.The expression of Cripto-1 negatively correlated with E-CD (r=0.324, P=0.000) and positively correlated with β-catenin which was expressed in the plasma of tumor cells (t=0.412,P=0.000).(3) Mann-Whitney test showed that the level of expression in the lymph node-positive group was higher than that in lymph node-negative group (z=-3.465,P=0.001).The expression was higher in the metastatic group than in the non-metastatic group (z=-3.899,P=0.000).Univariate Kaplan-Meier analyses revealed there was negative correlation between overexpression of Cripto-1 and survival (P0.05).Cox-regression analysis indicated that the overexpression of Cripto-1 was an inde- pendent prognostic factor in breast cancer (HR,2.353).Conclusion: Cripto-1 may,through EMT,promote invasion and metastasis. Moreover,overexpression of Cripto-1 may prove to be of clinical value in breast cancer as an independent prognostic factor for improving the estimation of prognosis and guiding therapeutic decisions.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call